Overview
Built on the backbone of oxyntomodulin, a naturally occurring gut hormone that hits both the GLP-1 and glucagon receptors. It is the first of the glucagon co-agonists to reach approval anywhere, in China, ahead of the Western programs.
Limited or non-US approvalPrescription medicine in China. Unapproved elsewhere; import for personal use is legally constrained.
| Regulatory status | Approved in China for weight management and type 2 diabetes. Not approved in the US, EU or UK. |
|---|---|
| Drug class | Dual glucagon / GLP-1 receptor agonist based on oxyntomodulin |
| Route | Subcutaneous, once weekly |
| Half-life | ~5–7 days |
| Evidence rating |
4/5 Strong
Evidence rating 4 out of 5: Strong
Consistent human randomized trials, or approval outside the United States. |
| Studied in | GLORY and DREAMS phase 3 programs in Chinese populations for obesity and type 2 diabetes. |
How it works
Oxyntomodulin-derived dual agonism at the GLP-1 and glucagon receptors, reproducing an endogenous signalling pattern rather than engineering one from scratch. Appetite suppression plus increased energy expenditure and hepatic fat oxidation.
Evidence base
Rated 4 of 5 — Strong. Consistent human randomized trials, or approval outside the United States.
- Genuine phase 3 evidence and a real approval — but in one jurisdiction only.
Benefits & potential uses
Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.
-
Phase 3 weight loss with regulatory approval Strong evidence
Phase 3 trials supported approval in China, with mean weight reductions in the mid-teens percent range at the higher dose.
-
Glycemic control in type 2 diabetes Strong evidence
Separate phase 3 program demonstrated HbA1c reduction sufficient for a diabetes indication.
-
Liver fat reduction Moderate evidence
Consistent with the glucagon component; reported across trials.
-
Endogenous hormone template Moderate evidence
Derived from oxyntomodulin rather than a synthetic chimera, which may explain its tolerability profile.
Risks, cons & cautions
Bars indicate seriousness: three = serious or common, two = moderate, one = minor.
-
No FDA or EMA approval Moderate evidence
Approval is limited to China. Western regulators have not reviewed the dossier.
-
Trial populations may not generalise Moderate evidence
The phase 3 program was conducted largely in Chinese participants, who differ in baseline BMI and metabolic phenotype from Western obesity populations.
-
GI adverse effects Moderate evidence
Nausea, diarrhea and vomiting, dose-related as with the whole class.
-
Heart rate increase Moderate evidence
Class effect of glucagon co-agonism.
-
Grey-market import Serious
Widely sold to Western buyers outside any lawful channel.
Who should avoid it
- Medullary thyroid carcinoma or MEN2 history
- Pregnancy
- Prior pancreatitis (relative)
If used under medical supervision, monitor
- HbA1c and weight
- Heart rate
- Hydration and renal function during GI illness
Interactions
Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.
- Insulin and sulfonylureas — dose reduction usually required
- Oral drugs sensitive to gastric emptying rate
Regulatory & legal status
Prescription medicine in China. Unapproved elsewhere; import for personal use is legally constrained.
Infographic
Where to read further
We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.
- PubMed — all published literature on Mazdutide
- PubMed — randomized controlled trials only
- ClinicalTrials.gov — registered human trials
Related peptides in Metabolic & Weight
Terms used on this page
- Glucagon
- Glucagon is a 29-amino-acid pancreatic alpha-cell hormone that raises blood glucose by driving hepatic glycogenolysis and gluconeogenesis, and also increases energy expenditure.
- Glucagon-Like Peptide-1 (GLP-1)
- Glucagon-like peptide-1 is an incretin hormone released by intestinal L-cells after a meal that stimulates glucose-dependent insulin secretion and suppresses appetite.
- Satiety vs Satiation
- Satiation is the set of signals that ends a meal in progress, while satiety is the post-meal inhibition that determines how long it takes before eating begins again.
- Resting Energy Expenditure (REE)
- Resting energy expenditure is the energy a body uses at rest in a fasted, thermoneutral state, and it accounts for most of daily total energy expenditure.
- Agonist
- An agonist is a ligand that binds a receptor and stabilises its active conformation, producing a biological response rather than merely occupying the binding site.
- Phase 3 Trial
- A Phase 3 trial is the large confirmatory study, powered for a prespecified clinical endpoint, on which a marketing application and the resulting product label are built.
This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.